Global burden of disease due to smokeless tobacco consumption in adults: an updated analysis of data from 127 countries by Siddiqi, Kamran et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Global burden of disease due to smokeless tobacco
consumption in adults: an updated analysis of data from 127
countries
Citation for published version:
Siddiqi, K, Husain, S, Vidyasagaran, A, Readshaw, A, Mishu, MP & Sheikh, A 2020, 'Global burden of
disease due to smokeless tobacco consumption in adults: an updated analysis of data from 127 countries',
BMC Medicine, vol. 18, no. 1. https://doi.org/10.1186/s12916-020-01677-9
Digital Object Identifier (DOI):
10.1186/s12916-020-01677-9
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
BMC Medicine
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 22. Sep. 2020
RESEARCH ARTICLE Open Access
Global burden of disease due to smokeless
tobacco consumption in adults: an updated
analysis of data from 127 countries
Kamran Siddiqi1,2*, Scheherazade Husain1, Aishwarya Vidyasagaran1, Anne Readshaw1, Masuma Pervin Mishu1 and
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Abstract
Background: Smokeless tobacco (ST) is consumed by more than 300 million people worldwide. The distribution,
determinants and health risks of ST differ from that of smoking; hence, there is a need to highlight its distinct
health impact. We present the latest estimates of the global burden of disease due to ST use.
Methods: The ST-related disease burden was estimated for all countries reporting its use among adults. Using
systematic searches, we first identified country-specific prevalence of ST use in men and women. We then revised
our previously published disease risk estimates for oral, pharyngeal and oesophageal cancers and cardiovascular
diseases by updating our systematic reviews and meta-analyses of observational studies. The updated country-
specific prevalence of ST and disease risk estimates, including data up to 2019, allowed us to revise the population
attributable fraction (PAF) for ST for each country. Finally, we estimated the disease burden attributable to ST for
each country as a proportion of the DALYs lost and deaths reported in the 2017 Global Burden of Disease study.
Results: ST use in adults was reported in 127 countries; the highest rates of consumption were in South and
Southeast Asia. The risk estimates for cancers were also highest in this region. In 2017, at least 2.5 million DALYs
and 90,791 lives were lost across the globe due to oral, pharyngeal and oesophageal cancers that can be attributed
to ST. Based on risk estimates obtained from the INTERHEART study, over 6 million DALYs and 258,006 lives were
lost from ischaemic heart disease that can be attributed to ST. Three-quarters of the ST-related disease burden was
among men. Geographically, > 85% of the ST-related burden was in South and Southeast Asia, India accounting for
70%, Pakistan for 7% and Bangladesh for 5% DALYs lost.
Conclusions: ST is used across the globe and poses a major public health threat predominantly in South and
Southeast Asia. While our disease risk estimates are based on a limited evidence of modest quality, the likely ST-
related disease burden is substantial. In high-burden countries, ST use needs to be regulated through
comprehensive implementation of the World Health Organization Framework Convention for Tobacco Control.
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Background
Smokeless tobacco (ST) refers to various tobacco-
containing products that are consumed by chewing, keep-
ing in the mouth or sniffing, rather than smoking [1]. ST
products of many different sorts are used by people in
every inhabited continent of the world (Table 1) [1]. For
example, in Africa, toombak and snuff are commonly
used, while in South America, chimó is the product of
choice. In Australia, indigenous people use pituri or min-
gkulpa [2], and in Central Asia, nasvay consumption is
very common. In North America, plug or snuff are
favoured, and even in Western Europe, where ST products
are largely banned, there are exemptions allowing people
in Nordic countries to use snus [3]. All the above products
vary in their preparation methods, composition and asso-
ciated health risks (Table 1), but it is in South and South-
east Asia where the greatest diversity of ST products
exists, accompanied by the highest prevalence of use [4].
Here, the level of cultural acceptability is such that ST
products are often served like confectionery at weddings
and other social occasions.
ST products contain nicotine and are highly addictive.
Often, they also contain carcinogens, such as tobacco-
specific nitrosamines (TSNA), arsenic, beryllium, cad-
mium, nickel, chromium, nitrite and nitrate, in varying
levels depending on the product [5, 6]. The pH of the
products also varies widely, with some (e.g. khaini,
zarda) listing slaked lime among their ingredients [7].
Raising the pH in this way increases the absorption of
nicotine and enhances the experience of using the ST
product, increasing the likelihood of dependence. The
elevated pH also increases the absorption of carcinogens,
leading to higher toxicity and greater risk of harm [7].
The harmful nature of many ST products, and the fact
that 300 million people around the world use ST [8], make
ST consumption a global public health issue. Many ST
products lead to different types of head and neck cancers
[9, 10]. An increased risk of cardiovascular deaths has
been reported [11], and its use in pregnancy is associated
with stillbirths and low birth weight [12, 13].
Because of the diversity described above, ST should
not be considered as a single product, but rather as
groups of products with differences in their toxicity and
addictiveness, depending on their composition. As a
consequence, it is difficult to estimate the global risks of
ST to human health and to agree on international pol-
icies for ST prevention and control. Several country-
specific studies [14, 15] have been carried out, and in
2015, we published an estimate of the global burden of
disease associated with ST use [16]. We used a novel ap-
proach, whereby we classified ST products according to
their availability in different geographical regions of the
world. For example, ST products in South Asia pose a
much greater risk to health than those available in
Nordic countries, where the manufacturing process
removes many of the toxins from the finished product
[6, 17]. Using this approach, we estimated the worldwide
burden of disease attributable to ST consumption, mea-
sured in terms of disability adjusted life years (DALYs)
lost and the numbers of deaths in 2010 [16]. Here, we
update this estimate to include data up to 2019, provid-
ing an indication of how the global ST arena has chan-
ged in the intervening years.
Methods
Our methods for updating the estimates of ST disease
burden were broadly the same as those used in our earl-
ier publication; these are well described elsewhere [16].
Here, we will summarise these methods and explain any
modification made, particularly in relation to the revised
timelines. We assessed disease burden for individual
countries by varying their populations’ exposure to ST,
using the comparative risk assessment method [15].
These individual estimates were then summarised for 14
World Health Organization (WHO) sub-regions (Add-
itional file 1: Appendix 1) as well as for the world.
We first searched the literature to identify the latest
point prevalence of ST use among adults ≥ 15 years in
men and women for each country (see Additional file 1:
Appendix 2 for detailed methods). We searched for the
latest estimates for x countries included in our previous
study as well as those additional y countries where esti-
mates have been made available since 2014 for the first
time. We derived single estimates for each country pre-
ferring nationally representative surveys using inter-
nationally comparable methods over non-standardised
national or sub-national surveys.
We also updated risk estimates for individual diseases
caused by ST; however, we kept to the original list of
conditions, i.e. cancers of the oral cavity, pharynx and
oesophagus, ischemic heart disease and stroke. We only
searched for papers published since our last literature
search; our updated search strategies can be found in
Additional file 1: Appendix 3. As before, all searches and
data extraction were independently scrutinised by a sec-
ond researcher and any discrepancies were arbitrated by
a third researcher. All case definitions for diseases and
exposure (ST use) used in the retrieved articles were
checked for accuracy and consistency and all analyses
undertaken in these studies were assessed to see if they
controlled for key confounders (mainly smoking and al-
cohol). We assessed study quality using the Newcastle-
Ottawa Scale for assessing non-randomised studies in
meta-analysis [24]. For all new studies, we log trans-
formed their risk estimates and 95% confidence intervals
to effect sizes and standard errors and added these to
the rerun of our random-effects meta-analyses to esti-
mate pooled risk estimates for individual conditions.
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Where possible, we pooled effect sizes to obtain country-
specific risk estimates. For all outcomes in the meta-
analyses, we conducted a GRADE assessment to assess the
quality of evidence. We also pooled these effect sizes to
obtain non-specific global risk estimates. Given that the
risk varies from country to country, depending upon
which products are locally popular, we used country-
specific risk estimates where possible. In countries with no
estimates, we used estimates of those countries where
similar ST products were consumed. For other countries
without estimates that consumed ST products known to
contain high levels of TSNAs, we applied non-specific glo-
bal estimates. Where no information was available on the
composition of ST, we did not apply any estimates. Details
on how these statistically significant estimates were ap-
plied to each WHO sub-region can be found in web Add-
itional file 1: Appendix 4.
Based on the extent to which the included studies ad-
justed for potential confounders, we categorised them as
‘best-adjusted’ and ‘others’. We carried out a sensitivity
analysis for all risks and attributable disease burden esti-
mates including only ‘best-adjusted’ studies. A sensitivity
analysis was also carried out by estimating risk estimates
separating out cohort from case-control studies.
For each country, we used their point prevalence of
ST use and the allocated risk estimate for each condition
to estimate its population attributable fraction (PAF) as
below:
PAF ¼ Pe RRe−1ð Þ= 1þ Pe RRe−1ð Þ½ 
Pe ¼ Prevalence RRe ¼ Relative risk
Using the 2017 Global Burden of Disease (GBD)
Study, we also extracted the total disease burden (B) in
terms of number of deaths and DALYs lost due to the
conditions associated with ST use for both men and
women. The attributable burden (AB) due to ST was
then estimated in deaths and DALYs lost for these con-
ditions for both men and women using the following
equation.
AB ¼ PAF B
Results
ST consumption was reported in 127 countries (Fig. 1).
These estimates were extracted from nationally repre-
sentative cross-sectional surveys conducted either as part
of international (97/127) or national (30/127) health and
tobacco surveillance (Additional file 1: Appendix 5a). A
variety of age ranges (as young as 15 or as old as 89, in-
cluding no upper age limit) were used to define adults.
ST consumption was more common among males
than females in 95 countries (Table 2). Among males,
Myanmar (62.2%), Nepal (31.3%), India (29.6%), Bhutan
(26.5%) and Sri Lanka (26.0%) had the highest consump-
tion rates. Among females, Mauritania (28.3%), Timor
Leste (26.8%), Bangladesh (24.8%), Myanmar (24.1%)
and Madagascar (19.6%) had the highest consumption
rates. Within Europe, Sweden (25.0% males, 7.0% fe-
males) and Norway (20.1% males, 6.0% females) had the
highest ST (snus) consumption rates.
Our post-2014 systematic literature search identified
an additional four studies demonstrating a causal associ-
ation between ST and oral cancer; these included two
Pakistan-based and one India-based case-control studies
and one US-based cohort study (Table 3). No new stud-
ies were found for pharyngeal and oesophageal cancers.
PRISMA flow diagrams describing the selection process
of the studies identified in the literature searches are
provided in Additional file 1: Appendix 5b,c. By adding
the new studies to the list of studies selected in our first
estimates and revising the meta-analyses, we found that
the pooled estimates were statistically significant for can-
cers of the mouth (Fig. 2). The non-specific pooled esti-
mate for oral cancers, based on 36 studies, were 3.94
(95% CI 2.70–5.76). The country-specific relative risk for
oral cancers for India was higher (RR 5.32, 95% CI 3.53–
8.02) than no-specific estimates and for the USA
remained statistically insignificant (RR 0.95, 95% CI
0.70–1.28). Since no new studies were added for
pharyngeal and oesophageal cancers, their non-specific
risk estimates of 2.23 (95% CI 1.55–3.20) and 2.17 (95%
CI 1.70–2.78) remained as per our original estimates, re-
spectively. For cardiovascular diseases, we identified an-
other three Swedish studies for ischaemic heart disease
and another two (one in Asia and one in Sweden) for
stroke (Table 3). In the absence of any new non-Swedish
studies on ischaemic heart disease (Fig. 3), we consid-
ered the relative risk (adjusted odds ratio 1.57, 95% CI
1.24–1.99) of myocardial infarction due to ST identified
in the 52-country INTERHEART study [35] (conducted
across nine WHO regions) as a valid estimate. However,
the country-specific (Sweden) relative risk for ischaemic
heart disease (RR 0.94, 95% CI 0.87–1.03) and both
country-specific (RR 1.02, 95% CI 0.93–1.13 [Sweden])
and non-specific relative risks for stroke (RR 1.03, 95%
CI 0.94–1.14) remained statistically insignificant. The
GRADE assessment was moderate for oral, pharyngeal
and oesophageal cancers and low for IHD (see Add-
itional file 1: Appendix 7).
We found that most of the included studies adjusted
for potential confounders (35/38 for oral, 10/10 for
pharyngeal and 15/16 for oesophageal cancers; and 13/
16 for IHD) and classified as providing ‘best adjusted’ es-
timates. According to a sensitivity analysis restricted to
only ‘best-adjusted’ studies, the overall risk estimates
(RR/OR) for oral cancer increased from 3.94 to 4.46 and
for oesophageal cancer from 2.17 to 2.22 (see Additional
Siddiqi et al. BMC Medicine          (2020) 18:222 Page 4 of 22
Fig. 1 Smokeless tobacco prevalence among men and women
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Table 2 Prevalence of smokeless tobacco use (%) in different countries of the world according to WHO sub-regional classification
WHO sub-regions Country M F Source Year
Africa (region D) Algeria* 10 0.8 Algeria Adult Tobacco Survey [25] 2010
Benin* 9 3 STEPS [26] 2015
Burkina Faso* 5.6 11.6 STEPS [26] 2013
Cameroon* 2.2 3.8 GATS [27] 2013
Cape Verde 3.5 5.8 STEPS [26] 2007*
Chad 1.9 0.4 STEPS [26] 2008
Comoros 7.72 2.99 DHS [28] 2012
Gabon 0.48 0.34 DHS [28] 2012
Gambia 0.8 1.4 STEPS [26] 2010 *
Ghana 1.33 0.2 DHS [28] 2008
Guinea 1.4 1.5 STEPS [26] 2009
Liberia* 1.1 3.1 STEPS [26] 2011
Madagascar 24.66 19.6 DHS [28] 2009
Mali 5 1.2 STEPS [26] 2007
Mauritania 5.7 28.3 STEPS [26] 2006
Niger 4.55 2.3 DHS [29] 2012
Nigeria* 2.9 0.9 GATS [27] 2012
Sao Tome & Principe 3.8 1.9 STEPS [26] 2009
Senegal* 0.3 1 GATS [27] 2015
Seychelles** 0.3 0.4 The Seychelles Heart Study IV [25] 2013–
14
Sierra Leone 2.9 12.1 STEPS [26] 2009
Togo 5.1 2.2 STEPS [26] 2010
Africa (region E) *Botswana* 1.5 6.5 STEPS [26] 2014
*Burundi 0.03 0.31 DHS [28] 2011
Congo (Brazzaville) 8.3 1.54 DHS [28] 2012
Congo (Republic) 8.67 3.22 DHS [28] 2013
Côte d’Ivoire 0.61 1.27 DHS [28] 2012
Eritrea* 11.6 0.1 STEPS [26] 2011
Ethiopia* 2.6 0.8 GATS [27] 2016
Kenya* 5.3 3.8 GATS [27] 2014
*Lesotho 1.3 9.1 DHS [29] 2009
*Malawi 1.9 5 STEPS [26] 2009
Mozambique 10.94 0.82 DHS [28] 2011
Namibia 1.8 2.3 DHS [29] 2006–
07
Rwanda* 0.6 3.3 STEPS [26] 2012
*South Africa* 1.4 8.4 South African Social Attitude Survey [25] 2007
Swaziland* 2.7 1.8 STEPS [26] 2014 *
*Tanzania 2.03 0.83 DHS [28] 2010
Uganda* 1.7 3 GATS [27] 2013
Zambia* 2.2 6.8 STEPS [26] 2017
Zimbabwe 1.6 0.4 DHS [30] 2011
Americas (region A) *Canada* 0.8 – CTADS [31] 2015*
USA 6.5 0.4 ICS [30] 2010
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Table 2 Prevalence of smokeless tobacco use (%) in different countries of the world according to WHO sub-regional classification
(Continued)
WHO sub-regions Country M F Source Year
Americas (region B) Argentina 0.1 0.2 GATS [27] 2012
Barbados 0 0.6 STEPS [26] 2007*
*Brazil 0.6 0.3 GATS [27] 2008
Costa Rica** 0.1 0 GATS [27] 2015
Dominican Republic 1.9 0.3 DHS [29] 2007*
Grenada 2.2 0.3 STEPS [26] 2011
Mexico* 0.4 0 GATS [27] 2015
Panama** 1 0.5 GATS [27] 2013
Paraguay 3 1.6 STEPS [25] 2011
St Kitts & Nevisa 0.3 0.1 STEPS [26] 2007
St Lucia** 1.3 0.2 STEPS [26] 2012*
Trinidad & Tobago 0.5 0.3 STEPS [26] 2011
*Uruguay** 0.3 – GATS [27] 2009
Venezuela 6.2 0.9 National Survey of Drugs in the General Population [25] 2011
Americas (region D) Haiti – 2.5 DHS [29] 2005–
06*
Eastern Mediterranean
(region B)
Kuwait** 0.5 0 STEPS [26] 2014
Libya 2.2 0.1 STEPS [26] 2009
Qatar** 1.3 0 GATS [27] 2013
Saudi Arabia* 1.5 0.3 Saudi Health Information Survey [25] 2014
Tunisia 8.6 2.2 ICS [30] 2005–
06
Eastern Mediterranean
(region D)
Egypt* 0.4 0 STEPS [26] 2017
Iraq* 0.4 0.02 STEPS [26] 2015
Morocco** 4.4 – STEPS [26] 2017
Pakistan* 11.4 3.7 GATS [27] 2014
Sudan* 14.3 0.2 STEPS [26] 2016
Yemen 13.7 4.8 National Health and Demographic Survey [25] 2013
Europe (region A) Austria* 2.8 0.5 Representative Survey on Substance Abuse [32] 2015
Belgium 1.1 0.6 SEBS [33] 2012
Cyprus 2.1 0.4 SEBS [33] 2012
Czech Republic* 2.2 1.2 The use of tobacco in the Czech Republic [25] 2015
Denmark* 2.3 0.9 Monitoring Smoking Habits in the Danish Population [25] 2015
Finland* 5.6 0.4 Health Behaviour and Health among the Finnish Adult
Population [25]
2014
France 1.2 0.6 SEBS [33] 2012
Germany 3.4 3.4 SEBS [33] 2012
Iceland* 13 3 May–December Household Surveys done by Gallup [25] 2015
Ireland 2.2 0.9 SEBS [33] 2012
Italy 1.8 1.5 SEBS [33] 2012
Luxembourg 1.8 1 SEBS [33] 2012
Malta 5.5 1.5 SEBS [33] 2012
Netherlands 0.3 0.1 The Dutch Continuous Survey of Smoking Habits [25] 2011
Norway* 21 6 Statistics Norway Smoking Habits Survey [25] 2015
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Table 2 Prevalence of smokeless tobacco use (%) in different countries of the world according to WHO sub-regional classification
(Continued)
WHO sub-regions Country M F Source Year
Portugal 4.4 1.1 SEBS [33] 2012
Slovenia 1.8 0.4 SEBS [33] 2012
Spain 0.4 0.2 SEBS [33] 2012
Sweden* 25 7 National Survey of Public Health [25] 2015
Switzerland* 4.2 1.2 Addiction Monitoring survey [25] 2013
United Kingdom 1.6 0.5 SEBS [33] 2012
Europe (Region B) Azerbaijan* 0.2 0 National study of risk factors for non-communicable diseases [25] 2011
Armenia 1.8 0 DHS [29] 2005
Bulgaria 0.3 0 SEBS [33] 2012
Georgia 1 0.2 Survey of Risk Factors of Non-Communicable Diseases [25] 2010
*Kazakhstan** 2.8 0 GATS [27] 2014
Kyrgyzstan* 10.1 0.1 STEPS [26] 2013
Poland 1 0.1 GATS [27] 2009
*Romania 0.4 0.2 GATS [27] 2011
Slovakia* 1.9 0.8 Tobacco and Health Education Survey [25] 2014
Uzbekistan* 23.2 0.2 STEPS [26] 2014
Europe (region C) Latvia* 0.1 0 Health Behaviour among Latvian Adult Population [25] 2014
Lithuania 1.2 0.2 SEBS [33] 2012
Moldova* 0.1 0 DHS [29] 2013
Russia* 0.8 0.1 GATS [27] 2016
Ukraine* 0.4 0 GATS [27] 2017
South East Asia (region B) Indonesia* 3.9 4.8 Basic Health Research [25] 2013
Sri Lanka* 26 5.3 STEPS [26] 2014
Thailand 1.1 5.2 GATS [27] 2011
South East Asia (region D) Bangladesh* 16.2 24.8 GATS [27] 2017
Bhutan* 26.5 11 STEPS [26] 2014
India* 29.6 12.8 GATS [27] 2017
Maldives* 3.9 1.4 STEPS [26] 2011
Myanmar* 62.2 24.1 STEPS [26] 2014
Nepal* 31.3 4.8 STEPS [26] 2013
Timor Leste* 16.1 26.8 National survey for non-communicable disease risk factors and
injuries [34]
2014
Western Pacific (region A) Australia* 0.6 0.3 National Drug Strategy Household Survey [25] 2013
Brunei Darussalam** 1.3 2.7 Knowledge, Attitudes and Practices Survey on Non-
communicable Diseases [25]
2014–
15
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file 1: sensitivity analysis #1). Separate risk estimates for
cohort and case-control studies are included in the Add-
itional file 1: sensitivity analysis #2).
The above risk estimates were included in the mathem-
atical model to estimate the population attributable frac-
tion (PAF), as follows (also see Additional file 1, Appendix
4 for detailed justification): For oral, pharyngeal and
oesophageal cancers, Sweden- and US-based country-
specific risk estimates were applied to Europe A and
America A regions, respectively. Similarly, India-based
country-specific risk estimates were applied to Southeast
Asia B and D and Western Pacific B regions. No risk esti-
mates were applied to Europe C due to the non-existence
of any risk estimates or information about the toxicity of
ST products. For all other regions, non-specific country
estimates were applied. A few exceptions were made to
the above assumptions: a Pakistan-based country-specific
estimate was applied for oral cancers for Pakistan and an
India-based estimate for the other two cancers; for the
UK, India-based country specific estimates were applied
due to the predominant use of South Asian products in
the country. For ischaemic heart disease, the INTER-
HEART disease estimates were applied to all WHO re-
gions except two, i.e. Europe A due to the availability of
Sweden-based country specific estimates and Europe C
due to the non-availability of relevant information. As pre-
viously stated, an exception was made for the UK and the
INTERHEART estimates were applied.
According to our 2017 estimates, 2,556,810 DALYs
lost and 90,791 deaths due to oral, pharyngeal and
oesophageal cancers can be attributed to ST use across
the globe (Table 4). By applying risk estimates obtained
from the INTERHEART study, 6,135,017 DALYs lost
and 258,006 deaths from ischaemic heart disease can be
attributed to ST use. The overall global disease burden
due to ST use amounts to 8,691,827 DALYs lost and
348,798 deaths. The attributable disease burden esti-
mates when restricted to only ‘best adjusted’ studies, did
not change significantly; the DALYs lost attributable to
ST increased to 8,698,142 and deaths to 349,222.
Among these figures, three quarters of the total dis-
ease burden was among men. Geographically, > 85% of
the disease burden was in South and Southeast Asia,
India accounting for 70%, Pakistan for 7% and
Bangladesh for 5% DALYs lost due to ST use (Additional
file 1: Appendix 6).
Discussion
ST consumption is now reported in at least two thirds
of all countries; however, health risks and the overall dis-
ease burden attributable to ST use vary widely depend-
ing on the composition, preparation and consumption of
these products. Southeast Asian countries share the
highest disease burden not only due to the popularity of
ST but also due to the carcinogenic properties of ST
products. In countries (e.g. Sweden) where ST products
are heavily regulated for their composition and the levels
of TSNAs, the risk to the population is minimal.
We found ST prevalence figures in 12 countries that
did not previously report ST use; new figures were also
obtained for 55 countries included in the previous esti-
mates [16]. Among these 55 countries: 19 reported a re-
duction in ST use among both men and women (e.g.
Bangladesh, India, Nepal), 14 only among men (e.g.
Laos, Pakistan) and eight only among women (e.g.
Bhutan, Sri Lanka) (Fig. 4a, b). On the other hand, 13
countries showed an incline in ST use among both men
and women (e.g. Indonesia, Myanmar, Malaysia, Timor
Table 2 Prevalence of smokeless tobacco use (%) in different countries of the world according to WHO sub-regional classification
(Continued)
WHO sub-regions Country M F Source Year
Western Pacific (region B) Cambodia* 0.8 8.6 National Adult Tobacco Survey of Cambodia [25] 2014
China 0.7 0 GATS [27] 2010
Lao People’s Democratic
Republic*
0.5 8.6 National Adult Tobacco Survey [25] 2015
Malaysia* 20.4 0.8 National Health And Morbidity Survey [25] 2015
Marshall Islands** 13.7 4 STEPS [26] 2002
Micronesia 22.4 3 STEPS [26] 2002
Mongolia* 0.8 0.2 STEPS [26] 2015
Niue** 0.3 0.2 STEPS [26] 2011
Philippines* 2.7 0.7 GATS [27] 2015
Vietnam* 0.8 2 GATS [27] 2015
CTADS Canadian Tobacco Alcohol and Drugs Survey, DHS the Demographic and Health Surveys, ICS Individual Country Survey, GATS Global Adult Tobacco Survey,
SEBS The Special Europe Barometer Survey, STEPS STEPwise approach to Surveillance, WHO World Health Organization
aPopulations of St Kitts and Nevis are tiny and unlikely to affect our estimates
*Countries included in the earlier paper (n = 55), but with updated values
**New countries not included in the earlier paper (n = 12)
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Leste) and one country (Sweden) among men only.
Overall, our updated ST-related disease burden in 2017
was substantially higher than that for 2010—by approxi-
mately 50% for cancers and 25% for ischaemic heart dis-
ease. This occurred despite a substantial reduction in ST
prevalence in India (constituting 70% of the disease bur-
den) and little change in the disease risk estimates. We
are now reporting ST use in 12 more countries;
however, the main reason for the increased burden of
disease was a global rise in the total mortality and
DALYs lost—oral, pharyngeal and oesophageal cancers,
in particular. The disease burden due to these cancers
lags several decades behind the risk exposure. Therefore,
a significant reduction in ST-related disease burden as a
result of a reduced prevalence will not become apparent
for some time to come. Among other studies estimating
Fig. 2 Risk estimates for oral cancers among ever ST users
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ST-related global disease burden, our mortality estimates
were far more conservative than those reported by Sinha
et al. (652,494 deaths); however, their methods were dif-
ferent from ours [9]. Moreover, Sinha et al.’s estimates
included a number of additional diseases such as cervical
cancer, stomach cancer and stroke. None of these risks
were substantiated in our systematic reviews and meta-
analyses. On the other hand, our estimates of 2,556,810
DALYs lost and 90,791 deaths due to cancers are close
to those estimated by the GBD Study for 2017, i.e.1,890,
882 DALYs lost and 75,962 deaths due to cancers [91].
A reason for the slight difference between these two esti-
mates might be that ours included pharyngeal cancers in
the estimates while GBD Study only included oral and
oesophageal cancers.
Our methods have several limitations. These have
been described in detail elsewhere [16] but are sum-
marised here. Our estimates were limited by the avail-
ability of reliable data and caveated by several
assumptions. The ST use prevalence data were not avail-
able for a third of countries despite reports of ST use
there. Where prevalence data were available, there were
Fig. 3 Risk estimates for cardiovascular diseases (ischaemic heart disease, stroke) among ever ST users
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Table 4 Number of deaths and DALYs lost from SLT use in 2017, by WHO sub-region as defined in Additional file 1: Appendix 1
WHO sub-regionsa Mouth cancer Pharyngeal cancer Oesophageal cancer Ischaemic heart disease All causes
M F All M F All M F All M F All M F All
Deaths
Africa D 184 83 267 120 37 157 294 124 418 3414 1497 4911 4012 1741 5753
Africa E 305 149 454 95 41 136 449 276 725 2231 1797 4027 3079 2263 5343
Americas A 0 0 0 0 0 0 0 0 0 10,298 565 10,863 10,298 565 10,863
Americas B 1189 112 1301 46 4 50 103 12 115 1275 260 1535 2613 389 3001
Americas D 0 3 3 0 1 1 0 2 2 0 76 76 0 82 82
Eastern
Mediterranean B
27 3 31 21 1 22 13 1 14 818 122 940 879 128 1007
Eastern
Mediterranean D
5488 3756 9244 611 138 749 752 269 1021 13,062 1982 15,045 19,913 6146 26,059
Europe A 69 14 84 30 3 33 246 42 288 0 0 0 346 60 405
Europe B 286 5 291 85 1 86 189 2 192 6552 163 6715 7112 170 7283
Europe C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Southeast Asia B 663 467 1130 394 148 542 260 123 383 5014 3349 8363 6330 4087 10,418
Southeast Asia D 25,966 9829 35,795 16,
378
4499 20,
876
9366 3493 12,
859
147,
065
50,509 197,
573
198,
774
68,329 267,
103
Western Pacific A 8 2 11 3 1 4 8 2 10 53 23 76 73 27 100
Western Pacific B 781 173 954 611 44 655 1841 49 1890 7084 798 7883 10,317 1065 11,382
Worldwide 34,966 14,
597
49,563 18,
394
4918 23,
312
13,
519
4397 17,
916
196,
867
61,140 258,
006
263,
746
85,052 348,
798
DALYs
Africa D 5350 2499 7849 3823 1245 5068 7860 3166 11,
027
78,500 31,152 109,
651
95,533 38,062 133,
595
Africa E 9242 4105 13,348 3174 1323 4497 12,
358
6590 18,
948
59,082 32,930 92,012 83,856 44,948 128,
804
Americas A 0 0 0 0 0 0 0 0 0 180,
756
6870 187,
626
180,
756
6870 187,
626
Americas B 2283 315 2598 1321 104 1425 2562 261 2823 28,177 4397 32,575 34,344 5077 39,421
Americas D 0 68 68 0 34 34 0 62 62 0 1745 1745 0 1909 1909
Eastern
Mediterranean B
758 90 848 593 42 634 301 23 324 16,420 1919 18,339 18,072 2073 20,145
Eastern
Mediterranean D
177,
353
126,
901
304,
254
19,
303
4655 23,
958
20,
904
7393 28,
298
324,
744
46,679 371,
423
542,
305
185,
628
727,
933
Europe A 1618 272 1890 686 76 763 4959 682 5641 0 0 0 7263 1030 8293
Europe B 5714 106 5820 2642 30 2672 4871 55 4926 141,
562
2177 143,
740
154,
789
2369 157,
158
Europe C 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Southeast Asia B 17,730 10,
792
28,523 11,
164
4319 15,
484
6608 2951 9558 122,
177
68,896 191,
073
157,
679
86,958 244,
637
Southeast Asia D 767,
549
258,
275
1,025,
824
471,
141
131,
531
602,
672
252,
556
87,
759
340,
314
3,697,
819
1,114,
976
4,812,
796
5,189,
065
1,592,
540
6,781,
606
Western Pacific A 201 48 249 78 15 93 166 24 191 809 233 1042 1255 320 1575
Western Pacific B 20,556 3795 24,351 18,
452
1324 19,
776
40,
948
1055 42,
003
157,
624
15,371 172,
995
237,
580
21,545 259,
124
Worldwide 1,008,
356
407,
266
1,415,
621
532,
378
144,
696
677,
074
354,
093
110,
021
464,
114
4,807,
671
1,327,
346
6,135,
017
6,702,
497
1,989,
330
8,691,
827
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very few studies providing country-specific disease
risks—a particular limitation in Africa and South Amer-
ica. In the absence of country-specific risk estimates, the
model relied on assuming that countries that share simi-
lar ST products also share similar disease risks. For ex-
ample, oral cancers risk estimates were only available
from five countries (India, Norway, Pakistan, Sweden
and the USA). For other countries, the extrapolated risks
were based on similarities between ST products sold
there and in the above five countries. The estimates for
ischemic heart disease must be interpreted with caution,
in particular, as the risk estimates for most countries
were extrapolated from a single (albeit multi-country)
study (INTERHEART). However, we excluded those re-
gions from the above extrapolation where the INTER-
HEART study was not conducted. As previously noted,
the total disease burden observed in 2017 is a
consequence of risk exposure over several decades.
Therefore, the attributable risk based on the prevalence
figures gathered in the last few years may not be accur-
ate. If ST prevalence has been declining in a country
over the last few decades, the disease burden obtained
by applying more recent prevalence figures may under-
estimate attributable disease burden. This may well be
the case in India where ST use has declined by 17% be-
tween the 2009 and 2017 GATS surveys [92]. On the
other hand, if ST use is on the rise (e.g. in Timor Leste),
the attributable disease burden for 2017 could be an
overestimate.
While we found a few more recent ST prevalence sur-
veys and observational studies on the risks associated
with ST use, big evidence gaps still remain. The ST sur-
veillance data for many countries are either absent or
outdated. The biggest gap is in the lack of observational
Fig. 4 a Countries with a proportional change in female ST use between 2015 and 2020 estimates. b Countries with a proportional change in
male ST use between 2015 and 2020 estimates
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studies on the risks associated with various types of ST
used both within and between countries. While longitu-
dinal studies take time, global surveillance of ST prod-
ucts, their chemical composition and risk profile can
help improve the precision of future estimates. As can-
cer registries become more established around the globe,
their secondary data analysis can also provide opportun-
ities to estimate ST-related risks.
ST is the main form of tobacco consumption by al-
most a quarter of all tobacco users in the world. Yet, its
regulation and control lags behind that of cigarettes.
The diversity in the composition and toxicity of ST
products and the role of both formal and informal sec-
tors in its production, distribution and sale make ST
regulation a particular challenge. In a recent policy re-
view of 180 countries that are signatories to WHO
FCTC, we found that only a handful of countries have
addressed ST control at par with cigarettes [93]. The
regulatory bar is often much lower for ST than cigarettes
[94]. Where ST control policies are present, there are
gaps in their enforcement [95]. On the other hand,
Sweden has demonstrated what can be achieved through
strong regulations; ST-related harm has not only been
reduced significantly, but snus is now used to reduce
harm from smoking. Countries where ST use is popular
and poses risks to health need to prioritise ST control
and apply WHO FCTC articles comprehensively and
evenly across all forms of tobacco.
Conclusions
ST is consumed across the globe and poses a major pub-
lic health threat predominantly in South and Southeast
Asia. While our disease risk estimates are based on a
limited number of studies with modest quality, the likely
disease burden attributable to ST is substantial. In high-
burden countries, ST use needs to be regulated through
comprehensive implementation and enforcement of the
WHO FCTC.
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